Join Growin Stock Community!

Traws pharma, inc.TRAW.US Overview

US StockHealthcare
(No presentation for TRAW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TRAW AI Insights

TRAW Overall Performance

TRAW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TRAW Recent Performance

2.42%

Traws pharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TRAW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TRAW Key Information

TRAW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TRAW Profile

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Price of TRAW

TRAW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TRAW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.63
PB Ratio
2.87
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
300.65%
Revenue Growth (YoY)
1134.51%
Profit Growth (YoY)
1134.51%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.63
PB Ratio
2.87
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
300.65%
Revenue Growth (YoY)
1134.51%
Profit Growth (YoY)
1134.51%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is TRAW's latest earnings report released?

    The most recent financial report for Traws pharma, inc. (TRAW) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TRAW's short-term business performance and financial health. For the latest updates on TRAW's earnings releases, visit this page regularly.

  • Where does TRAW fall in the P/E River chart?

    According to historical valuation range analysis, Traws pharma, inc. (TRAW)'s current price-to-earnings (P/E) ratio is 0.15, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How is TRAW's revenue growth?

    In the latest financial report, Traws pharma, inc. (TRAW) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does TRAW have?

    At the end of the period, Traws pharma, inc. (TRAW) held Total Cash and Cash Equivalents of 6.42M, accounting for 0.52 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TRAW's EPS continuing to grow?

    According to the past four quarterly reports, Traws pharma, inc. (TRAW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TRAW?

    Traws pharma, inc. (TRAW)'s Free Cash Flow (FCF) for the period is -4.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 65.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.